MedPath

Fluticasone propionate

Generic Name
Fluticasone propionate
Brand Names
Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
Drug Type
Small Molecule
Chemical Formula
C25H31F3O5S
CAS Number
80474-14-2
Unique Ingredient Identifier
O2GMZ0LF5W
Background

Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication

Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions
Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
Clinical Trials
Related News

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

First Posted Date
2023-01-25
Last Posted Date
2023-03-09
Lead Sponsor
Respirent Pharmaceuticals Co Ltd.
Target Recruit Count
34
Registration Number
NCT05697003
Locations
🇬🇷

BECRO Clinical Facility, Larissa, Thessaly, Greece

Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

Phase 3
Not yet recruiting
Conditions
Allergic Rhinitis
Interventions
Drug: MAZ-101association
First Posted Date
2023-01-13
Last Posted Date
2024-02-16
Lead Sponsor
EMS
Target Recruit Count
514
Registration Number
NCT05684380

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

First Posted Date
2022-12-23
Last Posted Date
2023-03-01
Lead Sponsor
Respirent Pharmaceuticals Co Ltd.
Target Recruit Count
451
Registration Number
NCT05664061
Locations
🇬🇷

BECRO Ltd., Athens, Greece

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

Phase 3
Active, not recruiting
Conditions
Eosinophilic Esophagitis
Interventions
Drug: Placebo oral tablet
Procedure: Esophagogastroduodenoscopy
First Posted Date
2022-12-02
Last Posted Date
2024-05-06
Lead Sponsor
Ellodi Pharmaceuticals, LP
Target Recruit Count
218
Registration Number
NCT05634746
Locations
🇺🇸

Centricity Research Columbus, Columbus, Ohio, United States

🇺🇸

Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

🇺🇸

TriWest Research Associates, LLC, San Diego, California, United States

and more 50 locations

A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Phase 1
Recruiting
Conditions
Eosinophilic Esophagitis
Interventions
First Posted Date
2022-11-08
Last Posted Date
2024-07-30
Lead Sponsor
Eupraxia Pharmaceuticals Inc.
Target Recruit Count
57
Registration Number
NCT05608681
Locations
🇦🇺

Princess Alexandra Hospital, Brisbane, Queensland, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇨🇦

McGill University Health Center, Montréal, Quebec, Canada

and more 2 locations

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Phase 2
Recruiting
Conditions
Skin Inflammation
Allergic Contact Dermatitis
Interventions
Other: Known patch test allergens
Device: Microneedle
Device: Suction blistering
Procedure: Skin punch biopsy
First Posted Date
2022-09-10
Last Posted Date
2024-05-23
Lead Sponsor
John Harris
Target Recruit Count
45
Registration Number
NCT05535738
Locations
🇺🇸

University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone

Active, not recruiting
Conditions
Asthma
Interventions
First Posted Date
2022-07-14
Last Posted Date
2023-07-19
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
75678
Registration Number
NCT05457855
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)

Phase 4
Completed
Conditions
Eosinophilic Esophagitis
Interventions
First Posted Date
2022-07-06
Last Posted Date
2024-11-07
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
23
Registration Number
NCT05444543
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

First Posted Date
2022-05-31
Last Posted Date
2022-05-31
Lead Sponsor
Respirent Pharmaceuticals Co Ltd.
Target Recruit Count
36
Registration Number
NCT05397834
Locations
🇬🇷

BECRO Clinical Facility, Larissa, Thessaly, Greece

To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma

Phase 3
Conditions
Bronchial Asthma
Interventions
Drug: Matching Placebo inhaler
First Posted Date
2022-05-05
Last Posted Date
2022-05-27
Lead Sponsor
Glenmark Pharmaceuticals Ltd. India
Target Recruit Count
790
Registration Number
NCT05363202
Locations
🇮🇳

Investigational Site 2, Aurangabad, Maharashtra, India

🇮🇳

Investigational Site 11, Nashik, Maharashtra, India

🇮🇳

Investigational Site 9, Ahmedabad, Gujarat, India

and more 8 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy